Literature DB >> 16414249

Antipsychotic type and correlates of antipsychotic treatment discontinuation in the outpatient treatment of schizophrenia.

Josep Maria Haro1, Diego Novick, Mark Belger, Peter B Jones.   

Abstract

Antipsychotic medication maintenance and the factors influencing it were analyzed using data from the SOHO study, a large observational study of the outcomes of antipsychotic treatment for schizophrenia in Europe. A total of 7186 adult patients in the outpatient setting who were initiating or changing their antipsychotic medication and who were prescribed only one antipsychotic after the baseline visit were analyzed. Medication maintenance at 12 months varied with the type of antipsychotic prescribed, being highest with clozapine (79.5%) and olanzapine (77.0%), and lowest with quetiapine (51.4%) and amisulpride (58.2%). Multiple logistic regression analysis demonstrated that the type of antipsychotic prescribed at baseline was the most important predictor of medication maintenance. Alcohol dependency, taking mood stabilizers, compulsory admission or arrest in the previous 6 months, greater clinical severity, and changing antipsychotic medication due to lack of effectiveness at baseline predicted a higher frequency of medication discontinuation in the subsequent 12 months. In contrast, medication maintenance was higher among patients who were treatment naïve at baseline, socially active or who had loss of libido at baseline. The findings from this study should be interpreted conservatively because of its non-randomized observational design.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16414249     DOI: 10.1016/j.eurpsy.2005.12.001

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  10 in total

Review 1.  Comparative effectiveness of atypical antipsychotics in schizophrenia: what have real-world trials taught us?

Authors:  Azizah Attard; David M Taylor
Journal:  CNS Drugs       Date:  2012-06-01       Impact factor: 5.749

Review 2.  The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia.

Authors:  Josep Maria Haro; Luis Salvador-Carulla
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

3.  Symptomatic remission in previously untreated patients with schizophrenia: 2-year results from the SOHO study.

Authors:  Diego Novick; Josep Maria Haro; David Suarez; Martin Lambert; Jean-Pierre Lépine; Dieter Naber
Journal:  Psychopharmacology (Berl)       Date:  2007-02-20       Impact factor: 4.530

4.  Risk factors for suicide behaviors in the observational schizophrenia outpatient health outcomes (SOHO) study.

Authors:  Roberto Brugnoli; Diego Novick; Josep Maria Haro; Andrea Rossi; Marco Bortolomasi; Sonia Frediani; Giuseppe Borgherini
Journal:  BMC Psychiatry       Date:  2012-07-19       Impact factor: 3.630

5.  Treatment discontinuation and clinical outcomes in the 1-year naturalistic treatment of patients with schizophrenia at risk of treatment nonadherence.

Authors:  Katarina Kelin; Timothy Lambert; Alan Jm Brnabic; Richard Newton; Wendy Ye; Raúl I Escamilla; Kuang-Peng Chen; Liana Don; William Montgomery; Jamie Karagianis; Haya Ascher-Svanum
Journal:  Patient Prefer Adherence       Date:  2011-05-09       Impact factor: 2.711

6.  Use of second-generation antipsychotics in the acute inpatient management of schizophrenia in the Middle East.

Authors:  Sulaiman Alkhadhari; Nasser Al Zain; Tarek Darwish; Suhail Khan; Tarek Okasha; Hisham Ramy; Talaat Matar Tadros
Journal:  Neuropsychiatr Dis Treat       Date:  2015-04-01       Impact factor: 2.570

7.  Clozapine as a first- or second-line treatment in schizophrenia: a systematic review and meta-analysis.

Authors:  C Okhuijsen-Pfeifer; E A H Huijsman; A Hasan; I E C Sommer; S Leucht; R S Kahn; J J Luykx
Journal:  Acta Psychiatr Scand       Date:  2018-09-14       Impact factor: 6.392

8.  Health and work disability outcomes in parents of patients with schizophrenia associated with antipsychotic exposure by the offspring.

Authors:  Heidi Taipale; Syed Rahman; Antti Tanskanen; Juha Mehtälä; Fabian Hoti; Erik Jedenius; Dana Enkusson; Amy Leval; Jan Sermon; Jari Tiihonen; Ellenor Mittendorfer-Rutz
Journal:  Sci Rep       Date:  2020-01-27       Impact factor: 4.379

9.  The Impact of Antipsychotic Formulations on Time to Medication Discontinuation in Patients with Schizophrenia: A Dutch Registry-Based Retrospective Cohort Study.

Authors:  Arnold P M van der Lee; Ibrahim Önsesveren; André I Wierdsma; Roos van Westrhenen; Aartjan T F Beekman; Lieuwe de Haan; Niels C L Mulder
Journal:  CNS Drugs       Date:  2021-04-10       Impact factor: 5.749

10.  Update on the management of symptoms in schizophrenia: focus on amisulpride.

Authors:  Ann M Mortimer
Journal:  Neuropsychiatr Dis Treat       Date:  2009-05-20       Impact factor: 2.570

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.